Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-12471 for Prevention of Cold-induced Vasospasm in Raynaud's Phenomenon
NCT01315899Phase 2Terminated
- Sponsor
- Orion Corporation
- Start
- Mar 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ORM-12471 in Raynaud's phenomenon (RP), sponsored by Orion Corporation. Started Mar 2011; status: terminated.
02
Drugs
ORM-12471
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT01315899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315899.